Kainos Medicine, Inc. (KOSDAQ:284620)

Market Cap	34.78B
Revenue (ttm)	n/a
Net Income (ttm)	39.92M
Shares Out	28.18M
EPS (ttm)	6.18
PE Ratio	199.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	98,277
Average Volume	498,879
Open	1,262.00
Previous Close	1,257.00
Day's Range	1,190.00 - 1,298.00
52-Week Range	1,141.00 - 7,100.00
Beta	1.24
RSI	42.08
Earnings Date	n/a

About Kainos Medicine

Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 284620